GlassScriptPhysician profile
Gary W Schlichter
NPI 1326031246
$1,229.10
in general payments reported to CMS, 2019-2025
22 companies · $79.63 in 2025
The $79.63 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $147 · 2021: $182 · 2022: $154 · 2023: $178 · 2024: $260 · 2025: $79.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $212.02 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $181.27 | 2019-2024 | |
| Sanofi Pasteur INC. | $116.29 | 2019-2023 | |
| Corium, LLC | $103.00 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $97.98 | 2020-2021 | |
| Tris Pharma INC | $94.37 | 2019-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Cranial Technologies, INC | $75.93 | 2019-2024 | Doc Band |
| Sobi, INC | $71.73 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $42.56 | 2019 | |
| Seqirus USA INC | $31.16 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.06 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $25.13 | 2025 | Bylvay |
| Astrazeneca Pharmaceuticals LP | $24.42 | 2023 | Flumist Quadrivalent |
| Biomerieux INC | $24.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Quidel Corporation | $20.97 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $20.24 | 2022 | |
| Neurelis, INC. | $18.52 | 2025 | Valtoco |
| Azurity Pharmaceuticals, INC. | $14.81 | 2025 | Alvesco |
| Adlon Therapeutics L.P. | $14.35 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.29 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Schlichter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.